Intramuscular Ketorolac at Two Single-Dose Regimens
Status:
Completed
Trial end date:
2020-11-09
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac
for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK
pain in a military emergency department (ED) that services Department of Defense (DoD),
Department of Veteran Affairs (VA), and foreign military beneficiaries